DOSTARLIMAB for Neoplasm: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 106 adverse event reports in the FDA FAERS database where DOSTARLIMAB was used for Neoplasm.
Most Reported Side Effects for DOSTARLIMAB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Malignant neoplasm progression | 111 | 12.4% | 38 | 17 |
| Thrombocytopenia | 42 | 4.7% | 0 | 17 |
| Fatigue | 38 | 4.3% | 1 | 12 |
| Anaemia | 36 | 4.0% | 9 | 17 |
| Death | 31 | 3.5% | 31 | 3 |
| Arthralgia | 30 | 3.4% | 1 | 9 |
| Diarrhoea | 29 | 3.3% | 3 | 14 |
| Rash | 29 | 3.3% | 0 | 14 |
| Condition aggravated | 27 | 3.0% | 7 | 14 |
| Dyspnoea | 26 | 2.9% | 2 | 20 |
| Nausea | 26 | 2.9% | 6 | 13 |
| Neuropathy peripheral | 26 | 2.9% | 2 | 4 |
| Abdominal pain | 25 | 2.8% | 3 | 20 |
| Off label use | 24 | 2.7% | 3 | 7 |
| Pyrexia | 24 | 2.7% | 2 | 16 |
Other Indications for DOSTARLIMAB
Endometrial cancer (315)
Ovarian cancer (119)
Endometrial cancer recurrent (115)
Cervix neoplasm (51)
Non-small cell lung cancer (51)
Product used for unknown indication (39)
Endometrial neoplasm (29)
Breast cancer (25)
Endometrial adenocarcinoma (25)
Endometrial cancer metastatic (16)
Other Drugs Used for Neoplasm
BEVACIZUMAB (502)
ATEZOLIZUMAB (404)
CYCLOPHOSPHAMIDE (385)
CARBOPLATIN (283)
PACLITAXEL (267)
NIVOLUMAB (219)
OXALIPLATIN (185)
PEMBROLIZUMAB (173)
LENALIDOMIDE (171)
DOXORUBICIN (150)